A systematic review on the efficacy and safety of IL-6 modulatory drugs in the treatment of COVID-19 patients

• Published in: European review for medical and pharmacological sciences Vol. 24; no. 13; p. 7475
• Main Authors: Solis-García Del Pozo, J, Galindo, M F, Nava, E, Jordán, J
• Format: Journal Article
• Language: English
• Published: Italy 01.07.2020
• Subjects: Antibodies, Monoclonal - pharmacology; Antibodies, Monoclonal, Humanized - pharmacology; Antiviral Agents - pharmacology; Betacoronavirus - drug effects; Betacoronavirus - immunology; Coronavirus Infections - diagnosis; Coronavirus Infections - drug therapy; Coronavirus Infections - immunology; COVID-19; Humans; Interleukin-6 - antagonists & inhibitors; Interleukin-6 - immunology; Pandemics - prevention & control; Pneumonia, Viral - diagnosis; Pneumonia, Viral - drug therapy; Pneumonia, Viral - immunology; SARS-CoV-2
• DOI: 10.26355/eurrev_202007_21916

The pandemic caused by the new SARS-CoV2 coronavirus has led to an effort to find treatments that are effective against this disease that the World Health Organization calls COVID-19. In severe cases of COVID-19, there is an increase in cytokines, among which IL-6 seems to play an important role. A search has been performed for studies using IL-6 blocking drugs (tocilizumab, siltuximab, and sarilumab) in PubMed, Web of Science, and Scopus. Also, a search of ongoing trials registered at clinicaltrials.gov was performed. We found very little published clinical experience with these drugs, consisting mainly of case reports or case series with few patients. The results of clinical trials are necessary to clarify the role of these drugs in patients with COVID-19.